Diagnosis and management of bipolar disorders
- PMID: 37045450
- DOI: 10.1136/bmj-2022-073591
Diagnosis and management of bipolar disorders
Abstract
Bipolar disorders (BDs) are recurrent and sometimes chronic disorders of mood that affect around 2% of the world's population and encompass a spectrum between severe elevated and excitable mood states (mania) to the dysphoria, low energy, and despondency of depressive episodes. The illness commonly starts in young adults and is a leading cause of disability and premature mortality. The clinical manifestations of bipolar disorder can be markedly varied between and within individuals across their lifespan. Early diagnosis is challenging and misdiagnoses are frequent, potentially resulting in missed early intervention and increasing the risk of iatrogenic harm. Over 15 approved treatments exist for the various phases of bipolar disorder, but outcomes are often suboptimal owing to insufficient efficacy, side effects, or lack of availability. Lithium, the first approved treatment for bipolar disorder, continues to be the most effective drug overall, although full remission is only seen in a subset of patients. Newer atypical antipsychotics are increasingly being found to be effective in the treatment of bipolar depression; however, their long term tolerability and safety are uncertain. For many with bipolar disorder, combination therapy and adjunctive psychotherapy might be necessary to treat symptoms across different phases of illness. Several classes of medications exist for treating bipolar disorder but predicting which medication is likely to be most effective or tolerable is not yet possible. As pathophysiological insights into the causes of bipolar disorders are revealed, a new era of targeted treatments aimed at causal mechanisms, be they pharmacological or psychosocial, will hopefully be developed. For the time being, however, clinical judgment, shared decision making, and empirical follow-up remain essential elements of clinical care. This review provides an overview of the clinical features, diagnostic subtypes, and major treatment modalities available to treat people with bipolar disorder, highlighting recent advances and ongoing therapeutic challenges.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: I have read and understood the BMJ policy on declaration of interests and declare no conflicts of interest.
Similar articles
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary.Med J Aust. 2018 Mar 19;208(5):219-225. doi: 10.5694/mja17.00658. Med J Aust. 2018. PMID: 29540132
-
Bipolar disorders.Lancet. 2020 Dec 5;396(10265):1841-1856. doi: 10.1016/S0140-6736(20)31544-0. Lancet. 2020. PMID: 33278937 Review.
-
Aripiprazole in acute mania and long-term treatment of bipolar disorder: a critical review by an Italian working group.Clin Drug Investig. 2010;30(12):827-841. doi: 10.2165/11584270-000000000-00000. Clin Drug Investig. 2010. PMID: 20923242 Review.
-
Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.Turk Psikiyatri Derg. 2021;32(4):293-295. doi: 10.5080/u26899. Turk Psikiyatri Derg. 2021. PMID: 34964106 English, Turkish.
Cited by
-
Early use of long-acting injectable antipsychotics in bipolar disorder type I: An expert consensus.Bipolar Disord. 2025 Feb;27(1):7-16. doi: 10.1111/bdi.13498. Epub 2024 Oct 22. Bipolar Disord. 2025. PMID: 39438154 Free PMC article. Review.
-
From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation.Int J Mol Sci. 2025 Mar 30;26(7):3219. doi: 10.3390/ijms26073219. Int J Mol Sci. 2025. PMID: 40244068 Free PMC article. Review.
-
Inositol Phosphates and Synthesizing Enzymes: Implications in Neurodegenerative Disorders.Biomolecules. 2025 Feb 4;15(2):225. doi: 10.3390/biom15020225. Biomolecules. 2025. PMID: 40001529 Free PMC article. Review.
-
Exploring pathological targets and advancing pharmacotherapy in autism spectrum disorder: Contributions of glial cells and heavy metals.Histol Histopathol. 2025 Jul;40(7):979-991. doi: 10.14670/HH-18-870. Epub 2025 Jan 3. Histol Histopathol. 2025. PMID: 39817414 Review.
-
Different prefrontal cortex activity patterns in bipolar and unipolar depression during verbal fluency tasks based on functional near infrared spectroscopy study.Sci Rep. 2025 Jul 1;15(1):21257. doi: 10.1038/s41598-025-05896-z. Sci Rep. 2025. PMID: 40593067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials